A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

Recruiting now. Registry record last updated June 25, 2026.

Who can join: Adults 18+, have obesity, BMI 30+.
What you take: cagrilintide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 18 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor Novo Nordisk A/SDrug cagrilintideClass OtherSites 11 USEnrollment target 114

What this study is for

Primary condition: Obesity. Also studied in: Overweight.

Full scientific study title: Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events.

Who can join

Age18 and upSexAnyBMI30 or higher

Adults 18+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Male or female (sex at birth)
Age 18 years or above at the time of signing the informed consent
History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m\^2)

Key exclusion criteria

Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
History of type 1 or type 2 diabetes
Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening
Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening

Where this trial is enrolling

This trial has 11 sites across 6 states. Contact a site coordinator directly to start screening.

Find a site near you

California1 site

Diablo Clinical Research, Inc.
Walnut Creek, California

Florida4 sites

Northeast Research Institute
Fleming Island, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
Encore Medical Research of Weston
Weston, Florida

North Carolina2 sites

Monroe Biomedical Research, LLC
Monroe, North Carolina
Accellacare
Wilmington, North Carolina

South Carolina1 site

Coastal Carolina Research Ctr
North Charleston, South Carolina

Tennessee1 site

Holston Medical Group_Bristol
Bristol, Tennessee

Texas2 sites

Amarillo Medical Specialists
Amarillo, Texas
Elligo Clin Res Centre
Austin, Texas

Follow this trial

We email you if NCT07607587 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: May 29, 2026. Expected completion: November 19, 2027. Last updated on ClinicalTrials.gov: June 25, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.